Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742567 | 0.91 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL21742862 | 0.82 | SLC6A7 (0.49) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL27018672 | 0.82 | BRD4 (0.44) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL16806048 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C19GAANPC1 | |
| SCHEMBL9444918 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL10599951 | 0.81 | KDM4E (0.45) | CYP1A2CYP3A4GAACYP2D6NPC1 | |
| SCHEMBL28133533 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL8365591 | 0.81 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| SCHEMBL13531392 | 0.79 | GAA (0.46) | CYP1A2CYP3A4CYP2C19GAACYP2D6 | |
| Ammonia Solution, Strong SCHEMBL27685788 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102238950-B | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use | CHDI FOUNDATION INC (US) | 2014-05-07 | — | — | CN | claimed |
| CN-102238950-A | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use | CHDI INC (US) | 2011-11-09 | — | — | CN | claimed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | claimed |
| CN-1324015-C | Pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | claimed |
| CN-1630644-A | Novel pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | CN | claimed |
| US-11825734-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2021222614-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-9905777-B2 | Compound and organic electroluminescence device comprising same | DOOSAN CORPORATION (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9905777-B2 | Compound and organic electroluminescence device comprising same | DOOSAN CORPORATION (KR) | 2018-02-27 | — | — | US | disclosed |
| WO-2018033082-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| WO-2017209487-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2017-12-07 | — | — | WO | disclosed |
| CN-1324015-C | Pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1630644-A | Novel pyridine and pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | CN | disclosed |
| US-H890-H | Herbicidal heterocyclicbenzylsulfonamides | Rorer, Morris P. (US) | 1991-02-05 | — | — | US | disclosed |
| US-4859670-A | 2-Azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, agents containing same, and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-22 | — | — | US | disclosed |
| US-4699649-A | Herbicidal heterocyclicbenzylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0237962-A2 | 2-Azolylmethyl-2-aryl-1,3-dioxolanes and their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-23 | — | — | EP | disclosed |
| EP-0164268-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11825734-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OSBP | CYP1A2 1592/4885CYP3A4 523/4885CYP2C19 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.